Faculty Profile

Mary Rinella
Section of Gastroenterology
Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730
Director, Metabolic and Fatty Liver Program

Academic Interests

Dr. Rinella's focus is in clinical research in the area of non-alcoholic fatty liver disease(NAFLD)/Nonalcoholic steatohepatitis (NASH) both before and after liver transplantation. She is actively involved in the American Association for the Study of Liver Diseases (AASLD) where she currently serves as Councilor-at-large on the Governing Board. She was an author on the 2018 AASLD Practice Guidance for NAFLD and the chair of the current AASLD NAFLD Practice Guidance. She has held several national leadership roles in the field of NAFLD including Chair of the AASLD NAFLD Special Interest Group (SIG) and currently as Chair of the AASLD NASH Task Force. As Chair of the NASH Task Force, she is charged with fostering research collaboration and advancing best practice through collaboration with other medical societies, federal agencies and patient advocacy organizations to improve outcomes in patients with NASH.

Clinical Interests

Non-alcoholic fatty liver disease, complex liver disease, liver tumors (Benign & Malignant),autoimmune liver disorders


  • Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Nature Reviews Gastroenterology Hepatology. 2021 Oct 27. doi: 10.1038/s41575-021-00523-4. Online ahead of print. PMID: 34707258
  • Powell E, Wong V and Rinella ME. Nonalcoholic fatty liver disease. Lancet, 2021. Apr 21;S0140-6736(20)32511-3.PMID: 33894145
  • Rinella ME, Dufour JF, Anstee Q, Goodman Z, Younossi Z, Harrison S, Loomba R, Sanyal AJ, Bonacci M, Tyrylinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. Journal of Hepatology 2021,Oct 29 PMID: 34793868
  • Younossi Z*, Ratziu V*, Loomba R, Rinella ME, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome P, Sheridan D, Sheikh M, Trotter J, Knapple W, Lawitz E, Abdelmalek M, Kowdley K, Montano-Loza A, Boursier J, MathurinP, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Lotte L, Gluud, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison SA, Sanyal AJ, on behalf of the REGENERATE Study. Obeticholic Acid for the Treatment 1 of Nonalcoholic Steatohepatitis-Interim Analysis From a Multicentre, Randomised, Placebo-Controlled Phase 3 Study. Lancet 2019 Dec 14;394(10215):2184-2196. PMID: 31813633
  • Rinella ME, Satapathy SK, Brandman D, Smith C, Elwir S, Xia J, Gibson M, Figueredo C, Angirekula M, Vanatta JA, Sarwar R, Jiang Y, Gregory D, Agostini T, Ko J, Podila P, Gallo G, Watt KD, Siddiqui Factors impacting survival in those transplanted for NASH cirrhosis: Data from the NailNASH Consortium. Clinical Gastroenterology and Hepatology 2022 Feb 18,


  • MD, 1996, Univ of Illinois at Chicago,
  • Residency, 1999, University of Chicago Hospitals, Internal Medicine
  • Fellowship, 2002, Northwestern University, Gastroenterology and Hepatology